Home
Questo sito è destinato ai professionisti sanitari.

Paradigmi in evoluzione nel carcinoma polmonare: Modulo 1 – Limiti degli attuali trattamenti

Condividi

Descrizione

Questa attività è supportata da un contributo educazionale indipendente della BioNTech-BMS Alliance. Questo programma di formazione online è stato ideato per i professionisti sanitari a livello globale.

Questo modulo di microlearning, guidato da esperti, esplora il panorama terapeutico in evoluzione per il tumore polmonare in stadio avanzato, esaminando i limiti degli attuali standard di cura e il ruolo emergente delle terapie bispecifiche PD-(L)1 × VEGF. Attraverso una revisione delle più recenti evidenze cliniche e del razionale biologico, il corpo docente fornisce spunti pratici su come questi nuovi agenti possano plasmare le future strategie terapeutiche e migliorare gli esiti clinici per i pazienti.

Preferisci leggere? Leggi qui la nostra Sintesi Clinica Principale.

Punti Salienti della Sessione

  • Esplorare i limiti delle attuali strategie terapeutiche per il NSCLC avanzato e il bisogno clinico insoddisfatto di approcci terapeutici più duraturi.
  • Comprendere il razionale scientifico del targeting duale PD-(L)1 × VEGF, incluso il suo potenziale nel superare l'immunosoppressione e l'angiogenesi tumorale.
  • Esaminare le più recenti evidenze cliniche a supporto delle terapie bispecifiche emergenti PD-(L)1 × VEGF e il loro ruolo potenziale nel panorama terapeutico in evoluzione.
  • Applicare le evidenze emergenti alla pratica clinica identificando come le nuove terapie bispecifiche possano influenzare le future decisioni terapeutiche e migliorare gli esiti per i pazienti.

Pubblico di Riferimento

Questa attività è rivolta a oncologi medici, pneumologi, infermieri specializzati, assistenti medici, farmacisti, infermieri e altri professionisti sanitari che si occupano della cura dei pazienti con tumore al polmone, inclusi il tumore del polmone non a piccole cellule (NSCLC) e il tumore del polmone a piccole cellule (SCLC).

Corpo Docente

Edward Garon, MD è Direttore del Programma di Oncologia Toracica presso il Jonsson Comprehensive Cancer Center dell'UCLA e Professore Associato presso l'UCLA. Oncologo toracico di spicco, i suoi interessi clinici e di ricerca si concentrano sul cancro al polmone, sullo sviluppo di biomarcatori e sull'innovazione delle sperimentazioni cliniche. Il Dott. Garon ha condotto numerosi studi clinici nazionali e internazionali di fase I-III, tra cui studi che hanno contribuito all'approvazione di molteplici terapie antitumorali e di un test diagnostico di accompagnamento.

Dichiarazioni sui Conflitti di Interesse (Disclosures)

In conformità con le linee guida EBAC®, tutti i relatori e moderatori che partecipano a questo programma hanno dichiarato o indicato eventuali potenziali conflitti di interesse che potrebbero influenzare le loro presentazioni. Il Comitato Organizzatore/Direttore del Corso è responsabile di garantire che tutti i potenziali conflitti di interesse rilevanti per l'evento siano resi noti al pubblico prima dell'inizio delle attività di formazione continua.

Il Dott. Edward Garon, docente per questa attività, ha dichiarato i seguenti rapporti finanziari negli ultimi 36 mesi con le seguenti aziende non idonee (ineligible companies):

Consulente e/o Advisor per: Abbvie; AstraZeneca; Arrivent; Bayer; Bicycle; Black Diamond Therapeutics; BridgeBio; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi-Sankyo; GSK; Gilead; Hexagon; I-Mab; IO Biotech; iTeos; Merck; Nuvalent; Oxford Bio; Pfizer; Regeneron; Samsung; Sanofi; Servier; Strata; Synthekine, Transcode; Verastem.

Supporto per Sovvenzioni/Ricerca (istituzionale) da: ABL-Bio; Arrivent; AstraZeneca; Bayer; BridgeBio; Bristol Myers Squibb; Daiichi Sanko; Eli Lilly; Genentech; Gilead; Iovance Biotherapeutics; Merck; Novartis; Prelude; Regeneron; Synthekine; TILT Biotherapeutics.

Proprietà Intellettuale per: Motif Neoepitopes for Cancer Immunotherapy

Il personale MedAll, così come i pianificatori e i revisori, non hanno rapporti finanziari rilevanti con aziende non idonee da dichiarare.

Informazioni ECM (CME) EBAC®

Questa attività è stata pianificata e implementata in conformità con i requisiti e le politiche di accreditamento dell'European Board for Accreditation of Continuing Education for Health Professionals (EBAC).

MedAll è un provider accreditato EBAC dal 2025. L'European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredita i programmi di Formazione Continua (CE) per la comunità medica internazionale.

Questo programma è accreditato dall'European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) per 15 minuti di tempo di formazione effettivo.

In conformità con le linee guida EBAC, tutti i relatori/presidenti che partecipano a questo programma hanno dichiarato o indicato potenziali conflitti di interesse che potrebbero causare distorsioni (bias) nelle presentazioni. Il Comitato Organizzatore/Direttore del Corso è responsabile di garantire che tutti i potenziali conflitti di interesse rilevanti per l'evento siano dichiarati al pubblico prima delle attività di CE.

L'EBAC® ha stipulato un accordo di mutuo riconoscimento di equivalenza sostanziale con l'US Accreditation Council for CME (ACCME) e il Royal College of Physicians and Surgeons of Canada, rispettivamente.

Tramite un accordo tra l'European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) e l'American Medical Association (AMA), i medici possono convertire i crediti CME esterni EBAC® in crediti AMA PRA Category 1. Le informazioni sulla procedura per convertire i crediti EBAC® in crediti AMA sono disponibili sul sito web dell'AMA. Altri professionisti sanitari possono ottenere dall'AMA un certificato di partecipazione a un'attività idonea per la conversione del credito in crediti AMA PRA Category 1.

L'Accreditation Council for Continuing Medical Education (ACCME) e il Royal College of Physicians and Surgeons of Canada hanno un accordo di equivalenza sostanziale dei sistemi di accreditamento con l'EBAC.

L'EBAC® è membro dell'International Academy for CPD Accreditation (IACPDA) e membro partner dell'International Association of Medical Regulatory Authorities (IAMRA).

Come ottenere i crediti CME EBAC®

Per ottenere il credito CME e ricevere il certificato, si prega di partecipare all'attività e completare la valutazione al termine. Si riceverà un link al certificato dopo aver completato la valutazione.

Costi di Partecipazione

La partecipazione a questo programma è gratuita.

Date di Validità:

Questa attività di formazione continua è attiva a partire dal 22 luglio 2026 e scadrà il 14 luglio 2027.

Tempo stimato per il completamento di questa attività: 15 Minuti

Community simili

Visualizza tutto

Eventi e video on-demand simili

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

I'm Edward Garin, and I will be, uh, in this segment addressing the limitations of current, uh, standard of care. And we will be focusing on non-small cell lung cancer. Before we begin, these are our disclosures. We will start with a polling question. Um, in this polling question, we have a 64 year old patient, uh, who has metastatic non-squamous, non-small cell lung cancer. The patient is Uh, discussing treatment options. And to explain why the oncology field is moving towards therapies that simultaneously target the immune system and tumor angiogenesis, uh, you as the practitioner, uh, referenced foundational trial data that combined, uh, PDL-1 inhibitor, uh, uh, an antibody along with an antibody directed against, uh, VEGF alongside standard chemotherapy. Um, based on the clinical data evaluating a PDL-1 inhibitor plus a VEGF inhibitor and chemotherapy, Um, in this case, it was, uh, otezallizumab, bevacizumab, carboplatin, and paclitaxel versus, uh, just a VEGF, uh, inhibitor and chemotherapy, uh, in this case, bevacizumab and carboplatin and paclitaxel. Uh, what was the hazard ratio for progression-free survival in the intention to treat population? Uh, the choices here are A, uh, has a ratio of less than 0.4, B, uh, has a ratio of, uh, 0.6 to 6.9. Uh, C, a hazard ratio of 0.7 to 0.8, or D, a hazard ratio of 0.8 or more. OK. We'll now go on to sort of the historic benchmarks. And um really, there's been a tremendous amount of progress over the last several years in the management of non-small cell lung cancer. And, um, we'll be speaking more about, uh, precision oncology later in, uh, in this presentation. Uh, but, uh, at least in the, the early 2000s, uh, really the only tools we had available to us were chemotherapy approaches. And what you can see here is that Uh, when multiple different chemotherapy approaches were evaluated, one versus the other, there really was very little difference. Um, there were some toxicity differences, but in terms of effectiveness, uh, what we saw was really the same. There also, and, and this is still actually a standard today, docetaxel was approved. Um, uh, uh, about 25 years ago, um, based on, uh, approval, uh, for improvements over, uh, best supportive care. And you can see the overall metrics here, um, which in many respects are somewhat disappointing. Pointing. At the time, the response rate was, uh, was about 7%, uh, with the median, uh, overall survival of 7 months. Uh, docetaxel does remain a standard of care. Um, interestingly, probably based on some improvements in things like supportive medications, um, we do have somewhat better outcomes with, uh, docetaxel. But, um, still, uh, our options in previously treated patients is limited. I would argue that for uh patients without driver mutations, uh, really the major advance in uh recent years has been, uh, the availability of immunotherapy. And, um, immunotherapy, it was originally approved in previously treated patients. Um, but that data really has now become largely irrelevant, as most people, certainly in the United States would receive a PD1 or PDL1 inhibitor, um, in the frontline setting. Now, there are multiple different, uh, agents that are approved. So I will not be going through the data on each, uh, but we'll be tending to go through sort of the first data set approved. Um, in an individual setting. And for, uh, patients in a frontline setting, the original approval was for monotherapy with pembrolizumab in patients with uh PDL1 expression in at least half of their tumor cells. Um, and you can see here with progression-free survival on the left, um, showing, uh, really tremendous benefits for this population of pembrolizumab over chemotherapy. And on the right, you can see the overall survival benefit, uh, again, showing very impressive hazard ratios. Uh, this, you know, certainly is exciting data. And over time, we have, uh, seen that, that these benefits, uh, are in many cases, uh, maintained. There is at this point, similar data in this upfront setting for patients who received, uh, emiblimab, uh, an alternate PD1 inhibitor, or the PDL1 inhibitor, otezlalizumab. One of the things that I think is particularly exciting, uh, about this class of agents is that there appear to be some patients that have true durable responses. And you can see, um, here is published data, um, from a five-year follow-up. There's now over 10-year follow-up on these patients from the original pembrolizumab study. You can see, uh, on the left here, um, is overall survival in treatment naive patients, um, which is really, I think today, the more relevant population than on the right, the, the previously treated patients. And you can see that, um, that really a, a good percentage of the patients Um, are alive 5 years after the initiation of therapy. Um, you can see that for the entire population, it's over 15% and nearly 30% for the population who had PDL1 in at least 50% of their tumor cells. As you are aware, there is now also data for chemotherapy. Um, and what you see here is data from the keynote 189 study showing progression-free survival above and overall survival when pembrolizumab is added to, uh, to chemotherapy. Um, the red is placebo, showing the chemotherapy alone. Um, there now is similar data along with chemotherapy for, uh, for cemiblimab, uh, as well. And as you can see here, um, even in these aggressive therapies, um, you can see those who have, uh, less than 1% PDL1 expression. Appear to have at least some numeric benefit, but it is not as great as, uh, as the other patients. And what you can also see is that the great majority of these patients have progressed, um, really even at, at a year. Um, and I think that, that, that is quite telling when one looks at the, uh, the overall survival on the right. Um, you can see still, um, benefits across the board. But outside of these patients with high PDL one expression, which are at the bottom, um, you know, most of these patients, uh, see a marginal benefit, um, really underscoring the importance, um, really in all patients of having additional options, um, that would, would improve. Obviously, there is a group who does very well, but we don't know upfront who those people always are. Um, here, you can see similar data. I won't go through the breakdown based on PDL one expression, but similar data on the left progression-free survival, the right and the overall survival, um, for squamous cell carcinoma, the prior data that I showed was for non-squamous disease. And again, you can see the addition of pembrolizumab, um, it does show an improvement, uh, over chemotherapy alone. Um, there are some other approaches that people have looked at. And one, Um, has been adding antiangiogenic therapy. Um, this is, uh, a data set that as we have started to see data coming back from by specific Uh, drugs that are targeting both, uh, PD1 or PDL1 along with, uh, VEGF or VEGF receptor. You can see that, uh, this has become, uh, sort of something that people have looked at more in this study. Um, otezallizumab, uh, along with bevacizumab, carboplatin, and paclitaxel was compared to the same regimen without, uh, otezlalizumab. Otezlalizumab, of course, is a PDL-1 inhibitor. And what you can see here is that uh the, there was a, a, a hazard ratio between 0.6 and 0.65 for um the addition of otezallizumab to bevacizumab, carboplatin, and, uh, paclitaxel. Uh, I'm not going to go too in-depth into um CTA4 inhibition. Uh, this is a somewhat controversial, uh, topic in, in the management of non-small cell lung cancer. Um, this is from the Checkmate 227 study. This is the schema for this study. And, um, as part of this study, patients were randomized based on PDL1 expression greater than or less than 1%, uh, to different arms, one of which in each arm, included, uh, a combination of devolumab along with ipilimumab. Um, this study did show, uh, good outcomes in those patients. Although it is hard to know how it would compare to, for instance, uh, the pembrolizumab chemotherapy, particularly in patients, uh, who were PDL1 positive. There are also regimens.